Infliximab in ulcerative colitis
Authors Levin A, Shibolet O
Published 12 September 2008 Volume 2008:2(3) Pages 379—388
Avi Levin, Oren Shibolet
Gastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, Israel
Abstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the treatment of moderate to severe UC.
Keywords: infliximab, ulcerative colitis, anti-TNF-α antibody, crohn’s disease
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]